Adagene (FRA:978) General and Admin. Expense: €6.09 Mil (TTM As of Dec. 2025)


FRA:978 Adagene Inc FRA:978
42 GF Score
Price €3.58
GF Value €11.98
! 5 Warning Signs
View Full Analysis

What is Adagene General and Admin. Expense?

Adagene FRA:978 -1.10% 42 General and Admin. Expense is €6.09 Mil as of Dec. 2025. GuruFocus rates FRA:978 with a GF Score™ of 42/100 and a GF Value™ of €11.98. The stock has 5 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Adagene's General and Admin. Expense for the six months ended in Dec. 2025 was €2.91 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €6.09 Mil.

Adagene General and Admin. Expense Related Terms

Adagene General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Adagene's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adagene General and Admin. Expense Chart

Adagene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial 12.78 11.21 7.95 6.95 6.04

Adagene Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.85 3.34 3.51 3.18 2.91
FRA:978
42GF Score
Adagene Inc FRA:978
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adagene General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €6.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of €6.09 Mil mean?
Adagene (FRA:978) has a General and Admin. Expense of €6.09 Mil as of Dec. 2025. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Adagene and its competitors.
Is Adagene's General and Admin. Expense too high?
Adagene's current General and Admin. Expense is €6.09 Mil. Overall, Adagene has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Adagene's General and Admin. Expense compare to RNAC and LYEL?
Adagene's General and Admin. Expense of €6.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Adagene and its competitors. Adagene's current General and Admin. Expense is €6.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adagene stock overvalued right now?
Adagene (FRA:978) has a current General and Admin. Expense of €6.09 Mil. The stock's GF Value™ is €11.98, compared to a current price of €3.58 — trading 70.1% below its estimated fair value. The current General and Admin. Expense is €6.09 Mil. Adagene's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Adagene (FRA:978), the current General and Admin. Expense is €6.09 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Adagene (FRA:978) Overvalued in 2026?

Based on GuruFocus' analysis, Adagene stock appears to be undervalued. The current stock price of €3.58 is trading 70.1% below its estimated GF Value™ of €11.98.

Key valuation signals for FRA:978:

  • General and Admin. Expense: €6.09 Mil
  • GF Value™: €11.98 vs. price of €3.58 (70.1% below fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the FRA:978 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Adagene Business Description

Other Exchanges ADAG:USA
Address Xinghu Street, Suzhou Industrial Park, 4th Floor, Building C14, No. 218, Jiangsu Province, Suzhou, CHN, 215123
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
42GF Score

Get the complete analysis for FRA:978

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.58
Price
€11.98
GF Value